Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) (MB)
Recruitment status was Recruiting
Background and Rationale: Inflammatory bowel disease (IBD) is a major burden to individuals and society. Ulcerative colitis and Crohn's disease (CD) are the 2 major inflammatory bowel diseases (IBD). They share some pathologic and clinical features but overall their pathogenesis is not resolved and diagnosis is sometimes difficult. The incidence rates range from 3.1 to 14.6 cases per 100,000 person year for Crohn's disease to 2.2 to 14.3 cases per 100,000 person years for ulcerative colitis and prevalence ranges up to 201/100,000 for Crohn's disease and up to 246/100,000 persons for ulcerative colitis.
Powerful biological therapies were recently introduced for the treatment of CD. They offer superior treatment for the treatment of steroid refractory patients. Interestingly newer studies suggest that these therapies might also be beneficial if not superior if used at earlier stages of the disease. But presently limitations of these treatments need to be considered and biomarkers that could better direct these treatments are urgently needed.
One present limitation is that these new therapies, though being beneficial in a large number of CD patients, will not be beneficial to all CD patients. Presently treatment responders and non-responders can not be identified prior to the treatment with the biological adalimumab representing an important unmet clinical need. Since adalimumab treatment can be accompanied by serious, potentially lethal, side effects, it would be a major advantage if future biomarkers could predict whether an individual will or will not respond to one or the other treatment.
Furthermore with treatments available being associated with high costs to patients and society, as the treatment with adalimumab is, biomarkers that would help to identify potential treatment-responders or non-responders would support their targeted use and would be appreciated by all stakeholders.
Nuclear magnetic resonance (NMR) spectroscopy is a method that generates comprehensive metabolic profiles from human biofluids, and these metabolomic profiles may be useful to identify biomarkers with discriminative and predictive power in CD. Thereby amongst other factors serum metabolites are affected by inflammation and urine metabolites are affected by gut flora and thus one or a combination of both may be a valuable tool in CD.
Aim: The investigators aim is to identify metabolomic predictors of clinical response to adalimumab treatment in CD patients in order to direct future treatment to a group of patients that is expected to benefit most.
Methods: Metabolomic profiling together with the collection of clinical data will be performed in patients with IBD prior to treatment with biological therapy and for up to 6 month thereafter.
In the study the investigators follow 50 patients with Crohn's Disease, naive to treatment with biologics. Metabolomic profiling will be performed 1 week prior to the treatment with adalimumab and then every 4 weeks for 6 month. In order to be reliable and reproducible, sampling will be performed in the morning after an overnight fasting period. On the days of serum/urine collection the following data will be collected: CBC, ESR, CRP, Calprotectin, ASCA/pANCA, IL-10, TNFα, IFNγ, Crohn's disease Activity Index, present medication and OTC, Dietary and lifestyle history including 24 hour dietary recall, alcohol intake, smoking and exercise.
Multivariate analysis will be performed to identify patterns in the metabolomic profile that predict response or non-response to adalimumab treatment.
To summarize, IBD is a major burden to patients and society. Adalimumab treatment is helpful in steroid refractory patients. Novel biomarkers that help physicians to decide which patient might benefit from adalimumab treatment may be powerful tools to optimize directing these powerful but expensive and side effect bearing therapies towards the patient that might benefit most. Metabolomic profiling may be the tool that helps us to identify these patients.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)|
- Treatment successfully defined by decrease of Disease Activity Index (DAI) of 3 or more at week 24 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- changes in metabolomic profile [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]The metabolic profil consists of 75 metabolites. These metabolites will be measured and changes will be captured.
- Change in CRP [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]CRP will be measured in blood serum
- change in medication use [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]Medication use will be recorded on every visit, changes in use will be captured.
Biospecimen Retention: Samples Without DNA
Serum, plasma and urine
|Study Start Date:||June 2010|
|Estimated Study Completion Date:||December 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Active Crohn's disease - single arm
Active Crohn's disease, a decision is made to start treatment with adalimumab.
|Contact: Martin Storr, MDemail@example.com|
|Contact: Jill Petkau||(403) firstname.lastname@example.org|
|Division of Gastroenterology||Recruiting|
|Calgary, Alberta, Canada, T2N 4N1|
|Contact: Brenda Nelson 403-592-5015 email@example.com|
|Principal Investigator: Martin Storr, MD|
|Sub-Investigator: Remo Panaccione, MD|
|Sub-Investigator: Subrata Ghosh, MD|
|Sub-Investigator: Cynthia Seow, MD|
|Principal Investigator:||Martin Storr, MD||University Calgary|
|Study Director:||Martin Storr, MD||University Calgary|